ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) announced today that the Company received a patent from the Mexico Patent and Trademark Office for the use of thymosin beta 4 (Tß4), its analogues, isoforms, and other derivatives, for preventing or healing the damage that occurs from a myocardial event, or heart attack. The patent expires in 2022. RegeneRx has similar patents pending in a number of countries, including the U.S. Based on recent clinical data, this year the Company filed additional worldwide patent applications, which, if granted, could potentially extend patent protection in this area until 2030.
